Significance and applicability of some inflammatory markers in patients undergoing hemodialysis
DOI:
https://doi.org/10.2478/AMB-2026-0070Keywords:
end-stage renal failure, hemodialysis, infectious complications, CRP, procalcitonin, IL-6, ferritin, uric acidAbstract
Abstract. Introduction: Patients with end-stage renal disease treated with hemodialysis are increasing worldwide, and the main reasons for their shortened survival are cardiovascular and infectious events. Aim: The aim of our study was to monitor the levels of the most commonly used inflammatory markers in practice and to clarify their applicability in this subgroup of patients. Materials and methods: We studied the values of C-reactive protein, interleukin-6, procalcitonin, ferritin, and uric acid in 69 patients treated with hemodialysis for more than 90 days. Those who had clinical evidence of infection or active neoplasm were excluded from the study. We compared the data with sex, age, main diagnosis, and vascular access. By age, patients were divided into those under and over 65 years of age. The data were processed with Statistical Package for Social Sciences (SPSS), version 20.0 (IBM Corp., Armonk, NY). Statgraphics Plus, version 2.1, and EXCEL for Windows. Results: We found that the data for procalcitonin, interleukin-6, ferritin, and uric acid were significantly higher than the reference values for healthy individuals. The only indicator that showed comparable values with healthy individuals was CRP. At the same time, the results for CRP and IL-6 were significantly higher in the groups over 65 years of age (0.025 and 0.006, respectively). Conclusion: According to our results, the only well-correlated and significant indicator in patients on hemodialysis treatment is CRP. Other markers should be used primarily to monitor the effect of the treatment.
References
Neuen BL, Chadban SJ, Demaio AR, et al. Chronic kidney disease and the global NCDs agenda. BMJ Glob Health. 2017 Jul 6;2(2):e000380. doi: 10.1136/bmjgh-2017-000380.
Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019 Nov;96(5):1048-1050. doi: 10.1016/j.kint.2019.07.012.
Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022;18(6):378-395.
United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020). https://usrds-adr.niddk.nih.gov/2022
Borisov B, Doroteya K. Changes in innate immunity in patients with chronic kidney disease. Current Trends in Immunology. 2021, 2, 35-41.
Eleftheriadis T, Liakopoulos V, Leivaditis K, et al. Infections in hemodialysis: a concise review - Part 1: bacteremia and respiratory infections. Hippokratia. 2011;15(1):12-17.
Johansen K, Gilbertson D, Shuling L, et al. US Renal Data System 2023 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases. 2024;83(4):A8-A13.
Silberzweig, J. Reducing Infections in Outpatient Hemodialysis: The Impact of Human Factors. American Journal of Kidney Diseases. 2024;84(1):4-5
Espi M, Koppe L, Fouque D, Thaunat O. Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. Toxins (Basel). 2020;12(5):300.
Espi M, Charmetant X, Fusil F, et al. Chronic Kidney Disease-Associated Defect in Humoral Immune Response Is Driven by Inflammation. Toxins 2026, 18, 104.
Fan SL, Miller NS, Lee J, Remick DG. Diagnosing sepsis – The role of laboratory medicine. Clin Chim Acta. 2016; 460:203-210.
Jungen MJ, Ter Meulen BC, van Osch T, et al. Inflammatory biomarkers in patients with sciatica: a systematic review. BMC Musculoskelet Disord. 2019;20(1):156.
Luan YY, Yao YM. The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases. Front Immunol. 2018;9:1302.
Li J, Hu L, Li L. C-Reactive Protein, Procalcitonin, and a Novel Pathogenesis and Therapeutic Target of Thrombocytopenia in Sepsis. Emerg Med Int. 2022; 2022:2498435.
Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167(1): 93-97.
Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993; 341(8844): 515-518.
Lippi G, Sanchis-Gomar F. Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. World J Gastroenterol. 2017; 23(47): 8283-8290.
Kip MMA, van Oers JA, Shajiei A, et al. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands. Crit Care. 2018; 22(1): 293.
Ivanov N, Mihailova S, Bilyukov R, et al. Changes in the cytokine profile in patients during COVID-19 infection. Acta Medica Bulgarica, 2023, 50 (4):5-12.
Abe R, Oda S, Sadahiro T, et al. Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Crit Care. 2010;14(2): R27.
Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401-409.
Gupta J, Mitra N, Kanetsky PA, et al. CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7:1938–1946.
Isaka Y, Takabatake Y, Takahashi A, et al. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890–896.
Gavrailova M, Elenkova A, Robeva R. Differences in metabolic parameters in patients with different degrees of obesity. Acta Medica Bulgarica, 2026, 53 (2):22-28.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 S. Aleksandrova, S. Linkova, N. Ramadan, E. Mineva-Dimitrova, B. Borisov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
